GlassScriptPhysician profile
Paul M Derose
NPI 1659573780
$37,195.38
in general payments reported to CMS, 2019-2025
27 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,098 · 2020: $4,615 · 2021: $137 · 2022: $714 · 2023: $26K · 2024: $687 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Honoraria: $2,505 · Food and Beverage: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,500.00 |
| Honoraria | $2,505.00 |
| Food and Beverage | $1,625.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure Gmbh | $22,500.00 | 2023 | Optune |
| Novocure INC. | $13,454.64 | 2019-2025 | Optune, Optune Gio |
| Astrazeneca Pharmaceuticals LP | $283.55 | 2019-2025 | Imfinzi, Lynparza |
| Sirtex Medical INC | $116.67 | 2019 | |
| Medtronic USA, INC. | $94.40 | 2019-2020 | |
| Allergan, INC. | $86.43 | 2019 | |
| Sobi, INC | $84.34 | 2023-2025 | |
| Janssen Biotech, INC. | $75.89 | 2021-2025 | Erleada, Rybrevant |
| Siemens Medical Solutions USA, INC. | $71.84 | 2022-2023 | Truebeam |
| Jazz Pharmaceuticals INC. | $70.35 | 2024-2025 | |
| Emd Serono, INC. | $40.83 | 2023 | Tepmetko, Bavencio |
| Amgen INC. | $32.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $31.87 | 2025 | |
| Taiho Oncology, INC. | $27.11 | 2022 | |
| Blue Earth Diagnostics | $25.64 | 2025 | Posluma |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.01 | 2022 | |
| Puma Biotechnology, INC. | $20.60 | 2022 | |
| Boston Scientific Corporation | $20.49 | 2019 | |
| Ge Healthcare | $19.70 | 2022 | |
| Celgene Corporation | $16.31 | 2022 | |
| Incyte Corporation | $16.26 | 2024 | Jakafi |
| Tactile Systems Technology INC | $16.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.40 | 2025 | Iclusig |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2019 | |
| Myriad Genetic Laboratories, INC. | $13.19 | 2023 | Precisetumor |
| Ipsen Biopharmaceuticals, INC | $12.63 | 2019 | |
| Aveo Pharmaceuticals, INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Derose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.